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Introduction {#s1}
============

Highly targeted radiotherapy of liver malignancies has found to be effective in selected patients. Stereotactic radiotherapy, radioembolization using yttrium-90 (^90^Y) microspheres as well as image-guided brachytherapy (BT) have been described in the literature with promising results [@pone.0112731-BodaHeggemann1], [@pone.0112731-Ricke1], [@pone.0112731-Seidensticker1]. A key limiting factor of these therapies is the relatively low tolerance of the liver parenchyma to radiation leading to either subclinical focal or generalized injury of the liver parenchyma. When the intensity or the extent of radiation-induced liver injury (RILI) exceeds the functional reserve, clinical complications appear in the form of radiation (radioembolization) induced liver disease (RILD or REILD) [@pone.0112731-Emami1], [@pone.0112731-Lawrence1], [@pone.0112731-Ricke2], [@pone.0112731-Seidensticker2]. Prior exposure or concomitant chemotherapy is thought to increase the risk of RILD (or REILD), and as a consequence is a relatively common complication, for example, after conditioning therapy prior to bone marrow transplantation (BMT) [@pone.0112731-Lawrence1], [@pone.0112731-McDonald1], [@pone.0112731-Sangro1], [@pone.0112731-Farthing1]. Liver damage whether associated with whole body irradiation or liver-directed radiotherapy have the same pathology, i.e. veno-occlusive disease (VOD) [@pone.0112731-Lawrence1], [@pone.0112731-Fajardo1], [@pone.0112731-Reed1], [@pone.0112731-Shulman1].

Medication designed to reduce RILI could improve the safety as well as enable more aggressive radiotherapy. Clinical studies have shown with varying strength of evidence that VOD/RILD after BMT can be ameliorated by pentoxifylline (PTX), ursodeoxycholic acid (UDCA) and low molecular weight heparin (LMWH) [@pone.0112731-Attal1], [@pone.0112731-Attal2], [@pone.0112731-Bianco1], [@pone.0112731-Essell1], [@pone.0112731-Forrest1], [@pone.0112731-Ohashi1], [@pone.0112731-Or1], [@pone.0112731-Ruutu1], [@pone.0112731-Clift1] (see [Table 1](#pone-0112731-t001){ref-type="table"}). However, the equivocal nature of the results from most studies probably reflect the heterogeneous study populations (including patients who have received prior chemotherapy or had underlying liver disease) [@pone.0112731-McDonald2]. Thus, a more standardized clinical model is needed to evaluate the protective effects of prophylactic regimens against VOD/RILD.

10.1371/journal.pone.0112731.t001

###### Summary of published studies on drug treatments for the prevention of VOD/RILD.

![](pone.0112731.t001){#pone-0112731-t001-1}

  Reference                                         Studydesign        N                                                                        Treatment regimen                                                                        Incidenceof VOD     p-value[\*](#nt101){ref-type="table-fn"}        Bilirubin(µmol/L)        p-value[\*](#nt101){ref-type="table-fn"}
  ------------------------------------------- ----------------------- ---- ----------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------------------------------ ----------------------------- ------------------------------------------
  Attal et al.1993 [@pone.0112731-Attal1]         ProspectiveRCT       70                                                    **Pentoxifylline** 1,600 mg/dday −8 to day+100 post-BMT                                                            4%                              NS                            26.4(mean max)                             NS
                                                                       70                                                                            Control                                                                                    3%                                                            24.4(mean max)         
  Clift et al.1993 [@pone.0112731-Clift1]         ProspectiveRCT       44                                               **Pentoxifylline** 2,400 mg/dday −3 to day+70 post-allogeneic BMT                                                       \-                                                            26.6(mean max)                            0.62
                                                                       44                                                                            Control                                                                                    \-                                                            23.47(mean max)        
  Bianco et al.1991 [@pone.0112731-Bianco1]         Phase 1--2         30                                          **Pentoxifylline** 1,200, 1,600,and 2,000 mg/d; day−10 to day+100 post-BMT                                                  10%                            0.001                                 \-                                   \-
                                                                       20                                                                    Control (retrospective)                                                                           65%                                                                  \-               
  Attal et al1992 [@pone.0112731-Attal2]          ProspectiveRCT       81                                         **Unfractionated heparin**100 U/kg/d cont. infusion;day −8 to day+30 post-BMT                                                2.5%                            0.01                          7.4%exceeding 34                          \<0.05
                                                                       80                                                                            Control                                                                                   14%                                                           18.7%exceeding 34       
  Forrest et al.2003 (18)                      Prospectivesingle-arm   40                                     **LMWH**: dalteparin 2500anti-Xa i.u; day −1 to day+30 post-BMT or hospitaldischarge                                      22.5%, 2.5% severe                                                                           
  Or et al.1996 [@pone.0112731-Or1]            ProspectiveRCT, pilot   61                                          **LMWH**: enoxaparin40 mg/day; day+1to day+40 post-BMTor hospital discharge                                                                                 0.01                     (duration ofelevatedlevels)                     0.01
                                                                       33                                                                            Control                                                                                                                                                                         
  Essel et al.1998 [@pone.0112731-Essell1]        ProspectiveRCT       34                                                  **UDCA** 600--1200 mg/d;day at least −1 to day+80 post-BMT                                                          15%                             0.03                           102.6(mean max)                           0.13
                                                                       32                                                                            Control                                                                                   40%                                                            188.1(mean max)        
  Ohashi et al.2000 [@pone.0112731-Ohashi1]       ProspectiveRCT       67                                                          **UDCA** 600 mg/d;day −21 to day+80post-BMT                                                                  3%                            0.004                        Not reportedin detail                         NS
                                                                       65                                                                            Control                                                                                  18.5%                                                        Not reportedin detail     
  Park et al.2002 [@pone.0112731-Park1]           ProspectiveRCT       82   **UDCA** 600 mg/d **+** **unfractionated heparin**5--50 U/kg/d adjusted aPTTof 50 s; day +1 to day +30post-BMT or hospitaldischarge (but aminimum of 15d)          16%                            0.348                           148.8(mean max)                          0.725
                                                                       83               **Unfractionated heparin**5--50 U/kg/d adjustedaPTT of 50 s; day +1 today +30 post-BMT orhospital discharge(but a minimum of 15d)                      19%                                                            173.6(mean max)        

\*Group comparison; LMWH: Low molecular weight heparin; BMT: Bone marrow transplantation; Max: Maximum; NS: Not significant; VOD: Veno-occlusive disease; RCT: Randomized controlled trial; UDCA: ursodeoxycholic acid (ursodiol); aPTT: activated Partial Thromboplastin Time.

Image-guided, single-fractioned, high-dose-rate BT of liver malignancies is associated with a well-characterized focal RILI (fRILI), which can be visualized and quantified using functional hepatobiliary magnetic resonance imaging (MRI) (see [Figure 1](#pone-0112731-g001){ref-type="fig"}) [@pone.0112731-Ricke2], [@pone.0112731-Seidensticker2]. Importantly, the histopathological evidence of fRILI (i.e. sinusoidal congestion with hepatocyte atrophy and increased reticulin deposits) correlates well with the absence of the hepatocyte uptake of hepatolbiliary MRI contrast media [@pone.0112731-Seidensticker3]. We have previously found that development of areas of fRILI were maximal at 6--8 weeks post-BT which correlates to the peak incidence of RILD/REILD after conditioning therapy/radioembolization througout the first 2 months post-intervention [@pone.0112731-Lawrence1], [@pone.0112731-Ricke2], [@pone.0112731-Seidensticker2], [@pone.0112731-Wybranski1]. We conducted a prospective study to quantify fRILI in patients who were randomized to BT with and without prophylactic PTX, UDCA and low-dose LMWH. To minimize the confounding effects of prior chemotherapy on radiation tolerability, only patients with liver metastases from colorectal cancer (mCRC) were included because these patients tend to have a more consistent pattern of prior exposition to chemotherapy. The cumulative effect of three drugs over a period of 8 weeks [@pone.0112731-Shulman2], [@pone.0112731-Lakshminarayanan1], [@pone.0112731-Park1] was assessed and patients followed-up at 6 and 12 weeks.

![T1w-axial THRIVE 20 min after application of Gd-EOB-DTPA (A, C--E and G, H) and BT planning CT with dosimetry (B and F).\
A--D, control group. A: pre-treatment MRI displaying a metastasis scheduled for BT treatment (black arrow). B: Planning-CT after introduction of the brachytherapy catheters (black arrows). Clinical target volume (CTV) represented by bold red circle and dosimetry by coloured lines (red: 20 Gy-, blue: 12 Gy-isodose). C: MRI at 6 weeks showing substantial reduction in Gd-EOB-DTPA uptake by liver parenchyma adjacent to treated metastases (i.e. focal radiation-induced liver injury, fRILI). Note: The area of fRILI matches the geometry of the dosimetry (B). Determined threshold dose: 9.75 Gy. D: MRI at 3 months showing shrinkage of the fRILI. Determined threshold dose: 11.9 Gy. E--H, treatment group. E: pre-treatment MRI displaying two metastases (black arrow); two more treated lesions are not displayed in the plane. F: Planning-CT (annotations: see B). G: MRI at 6 weeks showing no fRILI. H: MRI at 3 months after radiotherapy (and 1 month after finishing study treatment) showing a substantial region of fRILI. Determined threshold dose: 15.8 Gy.](pone.0112731.g001){#pone-0112731-g001}

Materials and Methods {#s2}
=====================

The protocol for this trial and supporting CONSORT checklist are available as supporting information; see [Checklist S1](#pone.0112731.s002){ref-type="supplementary-material"} and [Protocol S1](#pone.0112731.s003){ref-type="supplementary-material"}.

Study design {#s2a}
------------

This was a prospective, randomised phase II, parallel-group, open-label study conducted at a single centre. The study was approved by the competent authorities (Federal Institute for Drugs and Medical Devices (in german: Bundesinstitut für Arzneimittel und Medizinprodukte - BfArM)) and the local ethics committee (Ethikkommission der Otto-von-Guericke-Universität der Medizinischen Fakultät). Trial registration: Eudra-CT: 2008-002985-70; ClinicalTrials.gov-identifier NCT01149304. Written informed consent was obtained from all patients prior to study entry. Group allocation approach was unrestricted randomization.

Patient characteristics {#s2b}
-----------------------

Consecutive patients (18--80 years) with liver metastases from mCRC, who were scheduled for local ablation with computed-tomography (CT)/MRI-guided BT between 2009 and 2012, were screened ([Figure 2](#pone-0112731-g002){ref-type="fig"}). (BT is the local standard ablative treatment in patients ineligible for surgical or all other appropriate intervention).

![CONSORT-diagram.\
\*Exclusion criterion age was initially disregarded by error in this patient (aged 82). \*\*Exclusion criterion prior radiotherapy was initially disregarded by error in this patient (prior radiotherapy was performed 2 years earlier with location in the contralateral liver lobe).](pone.0112731.g002){#pone-0112731-g002}

Women who were pregnant, lactating or of childbearing potential were excluded as were patients with liver cirrhosis, hepatitis B or C, severe coronary artery disease, autoimmune diseases, acute bacterial endocarditis, active major bleedings or high-risk of uncontrolled hemorrhage; severe or moderate renal impairment (GFR \<60 mL/min), or known contraindication or hypersensitivity to any of the study treatments or procedures.

Treatment and follow-up {#s2c}
-----------------------

Patients received a single-fraction, CT- or MRI-guided BT of CRC liver metastases (see details below). In those randomized to prophylaxis, the following treatment was initiated during the evening of the day of BT: sc injection of 40 mg q.d. enoxaparin (Clexane, Sanofi Aventis, Paris, France) [@pone.0112731-Or1], oral 400 mg t.i.d. PTX (Trental, Sanofi Aventis) [@pone.0112731-Bianco1] and oral 250 mg t.i.d. UDCA (Ursofalk, Falk Pharma, Freiburg, Germany) [@pone.0112731-Essell1], [@pone.0112731-Ohashi1]. Patients were discharged usually on the third day post-BT and continued to take study medication at home for 8 weeks. All patients were followed-up on day 3, week 6 and 12 with an optional follow-up at week 24. Within 24 hours of the procedure and at each subsequent visit, blood samples were taken for liver-specific and inflammatory/hemostatic laboratory parameters, and patients were assessed for ECOG-performance status and health-related quality-of-life (using the EQ5D-questionnaire). All adverse reactions related to the study medication or BT were recorded.

Compliance to the prophylactic regimen was evaluated during a dialogue at each visit and the evaluation of anti-Xa-activity at 6 weeks. Insufficient compliance was determined by: either anti-Xa-activity \<0.1 IU/mL measured up to 4 hours after last enoxaparin injection, or two dose interruptions of the prophylactic regimen for more than 1 day/week. Non-compliant patients were withdrawn from the per-protocol analysis and study-specific medication stopped.

Image-guided interstitial brachytherapy {#s2d}
---------------------------------------

The technique of image-guided BT has been described previously [@pone.0112731-Ricke1]. Briefly, the placement of the introducer sheaths (6F Radiofocus, Terumo, Tokyo, Japan) with the BT applicators (Lumencath, Nucletron/Elekta, Veenendaal, The Netherlands) was performed using CT or MRI fluoroscopy. For treatment planning purposes, a spiral CT or T1-weighted MRI of the liver (reconstructed slice thickness: 3 mm) enhanced by intravenous application of iodine contrast media (CT) or Gd-EOB-DTPA (MRI) was acquired.

The high-dose-rate afterloading system (Microselectron, Nucletron/Elekta, Veenendaal, The Netherlands) employed an iridium-192 source with a nominal activity of 10Ci (i.e. 370GBq); decay correction was performed daily. Relative coordinates (x, y, z) of the catheters were determined in the CT/MRI-data set and transferred to the treatment planning system (Oncentra, Nucletron/Elekta). Using these coordinates, the clinical target volume and the predefined minimum dose (20 Gy, delivered as a single fraction [@pone.0112731-Ricke1]), the software calculated a dosimetry and the duration of the iridium-192 source inside the BT catheters. A planning CT with dosimetry is displayed in [Figure 1B and F](#pone-0112731-g001){ref-type="fig"}.

Magnetic resonance imaging {#s2e}
--------------------------

MRI (Achieva 1.5T, Philips, Best, The Netherlands) using the hepatobiliary contrast medium Gd-EOB-DTPA (Primovist, Bayer Healthcare, Leverkusen, Germany) was performed 1 day before and 6 and 12 weeks post-BT. MR-sequence of events was as follows: axial 3D T1-weighted (T1-w) gradient echo THRIVE (T1-High-Resolution-Isotropic-Volume-Excitation) (Time-to-Echo/Time-to-Repetition 4/10 ms, flip-angle 10°) with fat-suppression pre-contrast, at 20 s, 60 s and 120 s and 20 minutes after iv 0.1 mL/kg bodyweight Gd-EOB-DTPA. The slice thickness was 3 mm. For the study-specific MRI volumetry, dynamic THRIVE at 60 s (for the exclusion of tumor progression/local recurrence) and hepatobiliary phase THRIVE 20 min after application of Gd-EOB-DTPA (for the determination of area of fRILI) were mandatory.

Identification of the radiation isodose (minimal hepatic threshold dose) that demarcated the border between the fRILI and functioning liver tissue (as defined by non-uptake and uptake of Gd-EOB-DTPA enhanced MRI, respectively) was performed as follows in a blinded matter.

The hepatobiliary phase THRIVE was transferred to the BT-planning software. Image registration of the hepatobiliary phase THRIVE to the contrast-enhanced planning CT/MRI (including the dosimetry) was performed by an isoscalar local semi-automated point-based 3D-3D image registration using predefined match points (3 or 4 corresponding landmarks restricted to liver structures). Registration was only accepted if the target area merged perfectly by visual assessment. As a result of this procedure, the software simultaneously displayed the treatment dosimetry and anatomical structures/fRILI of the hepatobiliary phase THRIVE. The volume of the liver parenchyma with radiation-induced impaired uptake of Gd-EOB-DTPA (i.e. fRILI) was determined. The isodose of the dosimetry encircling this volume was determined at five different axial levels and the mean of these values recorded. This dose resembles the dose which was formerly applied at the now demarcated rim of the fRILI, corresponding to the assumed minimal hepatic tolerance dose. To ensure a negligible registration error, the volume of fRILI was inserted into the dose-volume-histogram of the dosimetry. The corresponding isodose was stored. Results of the two methods showed a high correlation of 0.899 and 0.562 (p\<0.001 and p = 0.006) for 6 and 12 weeks, respectively. To minimize methodological errors, the mean isodose value of the two methods was taken. In case of more than one treated lesion, the mean of the determined isodoses was used. If no detectable fRILI was seen in follow-up, the minimal mean hepatic threshold dose was defined as the dose which was previously administered at the tumor margin (since an effect on the liver parenchyma above this dose level cannot be excluded). [Figure 1](#pone-0112731-g001){ref-type="fig"} illustrates the development and appearance of the fRILI in hepatobiliary phase THRIVE.

Endpoints and statistical analyses {#s2f}
----------------------------------

The aim of the study was to assess if a combination regimen of PTX, UDCA and low-dose LMWH for 8 weeks provided a preventive effect regarding irradiation damage to liver parenchyma (as resembled by the minimal mean threshold dose of the fRILI volume) at 6 weeks (primary endpoint) and at 12 weeks (secondary endpoint) after BT.

As additional descriptor, detectable fRILI in Gd-EOB-DTPA MRI (yes/no) was recorded at each follow-up. Further secondary objectives included the safety of the study treatment after BT including changes in bilirubin and albumin which were graded according to Common Terminology Criteria for Adverse Events version 3 (CTCAE3.0).

The relation between hepatocyte dysfunction and changes in the following liver-specific and inflammatory/hemostatic laboratory values were analysed: fibrinogen, factor-VIII-activity, interleukin-6, protein-C-activity, protein-S-activity, von-Willebrand-factor-activity and antithrombin-III-activity [@pone.0112731-Lee1].

Determination of sample size was based on the expected minimum between-group difference of 2.1 Gy (SD 2.3 Gy) for minimal mean hepatic threshold dose at 6 weeks after BT (from 9.9 Gy to 12 Gy) [@pone.0112731-Seidensticker2]. A sequential test with 2 stages according to the Pocock-design was used which yielded a total of 22 observations per group with a scheduled interim analysis after 11 observations per group when a = 0.025 and power 1-b = 0.8. Interim-analysis showed a significant difference between the groups regarding the primary variable with a one-sided p-value of 0.011. A one-sided p of \<0.0148 was necessary to terminate the study prematurely.

Statistical analysis was performed using SPSS (SPSS21, IBM, Chicago, Il, USA). Descriptive analysis of patient characteristics and laboratory findings was performed. The primary analysis was evaluated in the per protocol cohort and repeated in the intention-to-treat population as sensitivity analysis. Between-group differences in minimal mean hepatic threshold after BT at 6 and 12 weeks were compared using a two-sample *t*-tests, and evidence of detectable fRILI were compared using the Fisher's-exact-test. Possible confounding factors were evaluated using the Mann-Whitney-*U*-test for metric variables and the Fisher's-exact-test for categorical variables, and then between-group differences for the primary endpoint were evaluated with inclusion of the covariables (ANOVA and ANCOVA). The relationship between the minimal mean hepatic threshold dose and laboratory values was tested by Pearson's correlation and ANCOVA. Group comparison regarding ECOG and EQ5D was made by Mann-Whitney-*U*-test. Median overall survival was estimated by Kaplan-Meier (group comparison by log-rank test). A p-value of \<0.05 was statistically significant.

Results {#s3}
=======

Of 129 patients screened with liver metastases from colorectal cancer scheduled for BT, 30 patients were included in the study and 22 patients (11 per group) in the primary analyses of the per-protocol group (see CONSORT diagram, [Figure 2](#pone-0112731-g002){ref-type="fig"}). Demographic characteristics of randomized patients at screening are summarized in [Table 2](#pone-0112731-t002){ref-type="table"} and the baseline liver function and other laboratory parameters are presented in [Table 3](#pone-0112731-t003){ref-type="table"}. Group comparison revealed a similar distribution of possible confounders. A tendency towards a larger volume of significantly radiation exposed liver parenchyma (\>10 Gy) in the study treatment group ([Table 2](#pone-0112731-t002){ref-type="table"}) may have potentially lowered the hepatic tolerance dose in this group instead of increase it [@pone.0112731-Wybranski1].

10.1371/journal.pone.0112731.t002

###### Patient characteristics (per protocol analysis).

![](pone.0112731.t002){#pone-0112731-t002-2}

  Variable                                         Treatmentgroup (n = 11)   Control(n = 11)   p-value(betweengroup)[\*](#nt103){ref-type="table-fn"}
  ----------------------------------------------- ------------------------- ----------------- --------------------------------------------------------
  Sex (m/f)                                                  9/2                   8/3                                 1.000
  Age (years)                                            71.09±5.47            65.09±12.55                             0.408
  Weight (kg)                                            84.64±11.68           83.91±12.89                             0.592
  Height (cm)                                            174.09±6.79           172.64±6.90                             0.834
  ECOG at baseline (0/1/2)                                  6/4/1                 4/5/2                                0.370
  EQ5D visual analogue score                             72.36±14.56           76.36±13.02                             0.446
  History of liver surgery                                  45.5%                 45.5%                                1.000
  Steatosis hepatis                                         36.4%                 18.2%                                0.635
  Diabetes mellitus                                         18.2%                 27.3%                                1,000
  Chemotherapy pretreatment                                                                   
  Applied lines                                           1.00±0.63             1.00±0.45                              1.000
  no chemotherapy                                           18.2%                 9.1%                                   NA
  1 line                                                    63.6%                 81.8%                                0.672
  2 lines                                                   18.2%                 9.1%                                   NA
  Prior chemotherapy                                                                          
  Oxaliplatin                                               63.6%                 63.6%                                1.000
  Irinotecan                                                36.4%                 36.4%                                1.000
  Biologicals                                               54.5%                 54.5%                                1.000
  Number of treated metastases                            1.91±1.04             1.45±0.52                              0.382
  Maximum diameter of metastases (mm)                    37.18±12.91           29.45±11.79                             0.146
  Clinical target volume (cm^3^)                         42.82±29.26           31.36±37.14                             0.156
  Number of used brachytherapy catheters                  3.18±1.78             2.27±1.74                              0.079
  Liver volume (cm^3^)                                  1296.1±226.6          1451.3±278.6                             0.401
  Interval between BT and 6 weeks FU (days)              43.91±4.76            45.09±4.68                              0.757
  Interval between BT and 3 months FU (days)             87.34±4.52            89.55±6.15                              0.505
  Liver volume with a dose exposure \>10 Gy (%)          22.55±14.45           11.95±10.43                             0.056
  Chemotherapy during follow-up                             18.2%                 9.1%                                 1.000

Continuous data: mean ± standard deviation, frequencies: counts or percent.

\*Group comparison, continuous data compared by Mann-Whitney U test, frequency data compared by Pearson's chi square test.

10.1371/journal.pone.0112731.t003

###### Laboratory parameters at baseline and follow-up (per protocol analysis).

![](pone.0112731.t003){#pone-0112731-t003-3}

  Variable(normal range)       Treatmentgroup (n = 11)   Control(n = 11)   p-value(betweengroup)[\*](#nt104){ref-type="table-fn"}   p-value(baseline *vs*.follow-up)[\*\*](#nt105){ref-type="table-fn"}  
  --------------------------- ------------------------- ----------------- -------------------------------------------------------- --------------------------------------------------------------------- -----------------------
  Bilirubin                           baseline              8.27±2.92                            8.39±5.61                                                         0.594                                 
  (\<21.0 µmol/L)                      6 weeks              9.58±9.94                            9.56±7.18                                                         0.641                                      0.182 (0.350)
                                      12 weeks              8.71±4.27                            8.75±5.95                                                         0.735                                      0.594 (0.505)
  Albumin                             baseline             44.21±3.46                            44.05±2.45                                                        0.833                                 
  (35.0--52.0 g/L)                     6 weeks             42.49±5.16                            42.67±3.17                                                        0.743                                      0.197 (0.060)
                                      12 weeks             42.84±4.94                            43.66±2.31                                                        0.743                                      0.212 (0.332)
  Cholinesterase                      baseline            149.26±47.97                          144.73±21.73                                                       0.718                                 
  (88--215 µmol/s.L)                   6 weeks            136.27±51.65                          143.82±29.10                                                       0.433                                    **0.023** (0.929)
                                      12 weeks            132.94±49.22                          153.36±30.96                                                       0.088                                    **0.010** (0.423)
  Aspartate transaminase              baseline              0.56±0.18                            0.46±0.17                                                         0.211                                 
  (0.17--0.83 µmol/s.L)                6 weeks              0.59±0.17                            0.55±0.23                                                         0.533                                    0.373 (**0.016**)
                                      12 weeks              0.63±0.47                            0.54±0.17                                                         0.974                                      0.563 (0.056)
  Alanine transaminase                baseline              0.44±0.20                            0.51±0.36                                                         1,000                                 
  (0.17--0.83 µmol/s.L)                6 weeks              0.50±0.18                            0.62±0.45                                                         0.742                                      0.443 (0.109)
                                      12 weeks              0.53±0.43                            0.52±0.27                                                         0.718                                      0.508 (0.722)
  Gamma glutamyltransferase           baseline              1.61±2.62                            1.49±1.21                                                         0.189                                 
  (0.17--1.19 µmol/s.L)                6 weeks              0.82±0.83                            2.21±1.71                                                       **0.011**                                    0.100 (0.050)
                                      12 weeks              1.25±1.17                            1.97±1.49                                                         0.139                                      0.722 (0.306)
  Glutamate dehydrogenase             baseline            104.36±91.47                          108.82±94.84                                                       0.844                                 
  (\<120 nmol/s.L)                     6 weeks             67.55±31.43                         123.27±105.88                                                       0.490                                      0.328 (0.308)
                                      12 weeks            128.11±108.79                         126.09±95.19                                                       0.849                                      0.674 (0.374)
  International normalized            baseline              93.9±3.03                            95.55±2.98                                                        0.053                                 
  ratio (0.85--1.27)                   6 weeks             94.11±2.71                            94.8±2.44                                                         0.399                                      0.438 (0.502)
                                      12 weeks             94.63±2.50                            95.33±3.61                                                        0.732                                      0.334 (0.498
  Interleukin 6                       baseline              4.54±3.31                            3.71±3.09                                                         0.245                                 
  (\<7.0 pg/mL)                        6 weeks              8.44±8.53                            7.62±4.41                                                         0.809                                      0.266 (0.038)
                                      12 weeks             10.50±9.24                            4.06±2.42                                                         0.229                                      0.139 (0.515)
  Fibrinogen                          baseline              3.72±0.53                            3.99±0.46                                                         0.377                                 
  (1.50--4.00 g/L)                     6 weeks              4.50±1.17                            4.77±0.84                                                         0.365                                  **0.014** (**0.017**)
                                      12 weeks              4.65±1.04                            4.23±0.49                                                         0.416                                    **0.037** (0.214)
  Factor VIII activity                baseline            169.09±41.51                          160.60±42.12                                                       0.756                                 
  (70--150%)                           6 weeks            195.45±61.02                          218.91±60.77                                                       0.490                                      0.130 (0.093)
                                      12 weeks             199.7±67.26                         257.09±150.23                                                       0.360                                    0.169 (**0.017**)
  Protein C activity                  baseline            107.36±33.99                          109.70±12.46                                                       0.145                                 
  (\>70%)                              6 weeks              108±32.68                           106.55±18.67                                                       0.767                                      0.799 (0.475)
                                      12 weeks             101.5±27.26                           114±19.76                                                         0.084                                      0.113 (0.540)
  Protein S activity                  baseline             85.36±12.26                          86.80±12.55                                                        0.848                                 
  (\>60%)                              6 weeks             82.18±15.16                          104.36±27.09                                                     **0.036**                                    0.266 (0.086)
                                      12 weeks             87.3±14.54                             91±10.6                                                          0.549                                      0.799 (0.507)
  von Willebrand factor               baseline            164.09±42.81                          174.90±71.14                                                       0.973                                 
  activity (70--130%)                  6 weeks            222.27±59.75                          201.73±71.76                                                       0.554                                    **0.013** (0.075)
                                      12 weeks             209.5±77.35                          215.27±75.31                                                       0.883                                    **0.013** (0.333)
  Antithrombin III activity           baseline             92.73±13.72                          98.90±11.50                                                        0.191                                 
  (\>80%)                              6 weeks             96.73±15.31                           98.2±9.78                                                         0.944                                      0.082 (0.779)
                                      12 weeks             96.4±12.08                            96.73±9.51                                                        0.751                                      0.407 (0.681)

\*Between group comparison, Mann-Whitney U test;

\*\*Comparison versus baseline (in brackets p-value of control group), Wilcoxon test.

The minimal mean hepatic threshold dose at 6 weeks after BT (primary endpoint) was significantly higher in the study treatment group than the control (19.1 Gy versus 14.6 Gy, p = 0.011, [Table 4](#pone-0112731-t004){ref-type="table"}) with comparable results with the intention-to-treat analysis ([Table 4](#pone-0112731-t004){ref-type="table"}). Correspondingly, fewer patients in the study treatment group than the control had evidence of fRILI at 6 weeks (45.5% versus 90.9%); this difference was also significant in the intention-to-treat analysis ([Table 4](#pone-0112731-t004){ref-type="table"}). However at 12 weeks after BT (and 4 weeks after cessation of study treatment), these between-group differences were not observed (in neither the per-protocol nor intention-to-treat analyses) for the minimal mean hepatic threshold dose and the proportion of patients with fRILI ([Table 4](#pone-0112731-t004){ref-type="table"}). Results from the optional follow-up at 24 weeks after BT continually showed no between-group differences for the minimal mean hepatic threshold dose and the proportion of patients with fRILI (no change of the proportion of patients with fRILI as compared to 12 weeks follow-up; the minimal mean hepatic threshold dose for treatment group was 20.1 Gy (1 patient missing) and for the control group 21.0 Gy; p\>0.05, per-protocol analysis (with comparable results with the intention-to-treat analysis)).

10.1371/journal.pone.0112731.t004

###### Minimal mean hepatic tolerance dose (Gy) and evidence of detectable focal radiation-induced liver injury (fRILI) after BT, group comparison.

![](pone.0112731.t004){#pone-0112731-t004-4}

  Variable                                                                Group                                                          p-value(between groups)
  -------------------------------------------------------------------- ----------- ---------------------------------- ----------------- -------------------------
  **Minimal mean hepatic** **tolerance dose** **(primary endpoint)**                         **Dose (Gy)**                 **SD**       
  At 6 weeks                                                             Control            14.64 \[14.15\]             4.01 \[3.93\]   
                                                                        Treatment           19.06 \[18.46\]             3.35 \[3.59\]    **0.011** \[**0.007**\]
  At 12 weeks                                                            Control            16.38 \[16.10\]             3.57 \[3.60\]   
                                                                        Treatment           19.04 \[18.50\]             2.88 \[3.11\]        0.069 \[0.082\]
  **Detectable fRILI**                                                                         **Counts**               **Frequency**   
  At 6 weeks                                                             Control        10 [@pone.0112731-Reed1]       90.9% \[92.3%\]  
                                                                        Treatment   5 [@pone.0112731-Seidensticker2]   45.5% \[53.8%\]   **0.022** \[**0.027**\]
  At 12 weeks                                                            Control        10 [@pone.0112731-Reed1]       90.9% \[92.3%\]  
                                                                        Treatment       10 [@pone.0112731-Reed1]       90.9% \[92.3%\]       1.000 \[1.000\]
                                                                                                                                        

Per protocol analysis (n = 22); Intention-to-treat analysis (n = 26) in square brackets.

Covariate analyses also showed no influence of recorded covariables on the primary endpoint; only group allocation was significant ([Table 5](#pone-0112731-t005){ref-type="table"}).

10.1371/journal.pone.0112731.t005

###### Covariate analysis of minimal mean hepatic tolerance dose 6 weeks after BT (per protocol, n = 22).
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  Covariate[\*](#nt107){ref-type="table-fn"}       p-value(group influence)   p-value(co-variate influence)
  ----------------------------------------------- -------------------------- -------------------------------
  Sex (m/f)                                               **0.015**                       0.458
  Age (y)                                                 **0.016**                       0.864
  Weight (kg)                                             **0.010**                       0.117
  Height (cm)                                             **0.011**                       0.485
  ECOG at baseline (0 and 1 vs 2)                         **0.008**                       0.310
  EQ5D visual analogue score                              **0.015**                       0.868
  History of liver surgery                                **0.007**                       0.064
  Steatosis hepatis                                       **0.014**                       0.845
  Diabetes mellitus                                       **0.015**                       0.627
  Chemotherapy pre treatment                              **0.012**                       0.373
  Used chemotherapeutic agents                                               
  Oxaliplatin                                             **0.013**                       0.991
  Irinotecan                                              **0.011**                       0.327
  Biologicals                                             **0.012**                       0.459
  Number of treated metastases                            **0.013**                       0.681
  Maximum diamter of metastases (mm)                      **0.023**                       0.669
  Clinical target volume (cm^3^)                          **0.013**                       0.815
  Liver volume (cm^3^)                                    **0.018**                       0.937
  Interval from BT to 6 weeks FU (days)                   **0.008**                       0.258
  Liver volume with a dose exposure \>10 Gy (%)           **0.013**                       0.598
  Chemotherapy during follow-up                           **0.015**                       0.191
  Bilirubin baseline                                      **0.030**                       0.401
  Albumin baseline                                        **0.020**                       0.784
  Aspartate transaminase baseline                         **0.025**                       0.263
  Alanine transaminase baseline                           **0.006**                       0.092
  Cholinesterase baseline                                 **0.013**                       0.425
  Gamma glutamyltransferase baseline                      **0.012**                       0.317
  Glutamate dehydrogenase baseline                        **0.011**                       0.352
  International normalized ratio baseline                 **0.008**                       0.783
  Interleukin 6 baseline                                  **0.030**                       0.401
  Fibrinogen baseline                                     **0.002**                       0.232
  Factor VIII activity baseline                           **0.005**                       0.615
  Protein C activity baseline                             **0.004**                       0.868
  Protein S activity baseline                             **0.004**                       0.831
  von Willebrand factor activity baseline                 **0.004**                       0.763
  Antithrombin III activity baseline                      **0.008**                       0.261

\*Two-way ANOVA for categorical factors, ANCOVA for metric covariables.

EQ5D (as a descriptor of quality of life) and distribution of ECOG performance status were not significantly different at baseline ([Table 2](#pone-0112731-t002){ref-type="table"}) or at any follow-up visit ([Table S1](#pone.0112731.s001){ref-type="supplementary-material"}). Median overall survival from time of BT on was not different between the groups with 30.0 months (95%CI: 8.7--51.3) in the treatment group and 39.5 months (27.5--51.5) in the control group (p = 0.430).

Safety analyses were conducted in all 30 patients who received BT. The following mild-to-moderate adverse events CTCAEv3 grade 1--2 were reported (in the treatment/control groups) on day 3 after BT: pain (1 patient/1 patient) and fatigue (0/1); at week 6: pain (2/0), fatigue (0/1), nausea (1/0) and diarrhea (2/0); nausea and diarrhea was probably related to PTX or UDCA. One grade 3 subacute bleeding episode from the bile duct, related to BT, occurred in the study treatment group which was successfully managed by endoscopic coagulation.

Analysis of the laboratory data revealed no grade 3/4 changes in bilirubin or albumin. One grade 1 reduction of albumin in the treatment group at 6 weeks was unchanged at week 12. One patient in control group with elevated (grade 1) bilirubin at baseline remained stable throughout follow-up. RILD was not observed on either group.

Laboratory analysis regarding liver-specific and inflammatory/hemostatic parameters found no relevant findings at baseline ([Table 3](#pone-0112731-t003){ref-type="table"}). At week 6, slightly higher gamma-glutamyl-transferase levels and protein-S-activity were recorded in the control group compared with the treatment group. At 6 and 12 weeks, there was slight but significant mean decrease from baseline in cholinesterase in the treatment group. Additionally, mean fibrinogen and von-Willebrand-factor-activity increased significantly from baseline in the treatment group at 6 and 12 weeks; while significant increases from baseline were recorded with mean fibrinogen, factor-VIII-activity and aspartate-transaminase in the control group at 6 weeks.

No correlation between the minimal mean hepatic threshold and liver-specific and inflammatory/hemostatic laboratory values was found at either week 6 or 12 (data not shown).

Discussion {#s4}
==========

In this prospective study, we were able to show a significant reduction in fRILI (as measured by hepatobiliary MRI) at 6 weeks after BT of colorectal liver metastases in patients who received low-dose LMWH, PTX and UDCA. Re-assessment of patients at 12 weeks (4 weeks after cessation of study treatment) found that the extent and incidence of fRILI was comparable to the control group, thereby supporting the reliability of our findings. This is further authenticated by the results of the (optional) 24 weeks follow-up. According to our results we believe that we were able to mitigate rather than delay the fRILI by the prophylactic regimen. The finding that the positive effect of the medication to the liver parenchyma as seen at the 6 weeks follow-up vanished after discontinuation of the medication (after 8 weeks) in the 3 months follow-up, make us believe that the fRILI was in fact mitigated in that period. Further on, the extent of the fRILI at 6 weeks in the treatment group and at 3 months (and 6 months) in both groups was less in size compared to the fRILI in the control group at 6 weeks (the peak of the fRILI in our study). Thus, the maximum extent of the fRILI at 6 weeks was skipped in the treatment group as compared to the control group. However, the radiation damage could not be suppressed completely by the prophylactic regimen with a rebound after cessation of the treatment to the level of the control group in later follow-ups. Thus, it is possibly right to assume additionally a delay on the development of the fRILI by the prophylactic regimen. This delay is considered to be advantageous as well since a rapid formation of the fRILI can be delayed (and mitigated) allowing the liver remnant to compensate for the fRILI. However, although appropriately powered, the study should be understood as a pilot due to the small sample size. To compensate for the rebound of the fRILI after cessation of the prophylactic regimen and for a better understanding of the dynamics of the fRILI, a study concept with a prolonged course for the prophylactic regimen is planned.

RILI remains a challenge in the treatment of liver malignancies by radiotherapy (whether percutaneous, interstitial or by radioembolization) because it may eventually translate into RILD or REILD. Further on, life-threatening VOD associated with combined-modality induced liver disease occurs in 5--60% of patients undergoing BMT [@pone.0112731-Forrest1], [@pone.0112731-McDonald2], [@pone.0112731-Shulman2]. For this reason, the potentially protective effects of a number of treatments including low-dose LMWH, PTX and UDCA have been evaluated. Although the efficacy appears equivocal in some studies [@pone.0112731-Attal1], [@pone.0112731-Attal2], [@pone.0112731-Bianco1], [@pone.0112731-Essell1], [@pone.0112731-Forrest1], [@pone.0112731-Ohashi1], [@pone.0112731-Or1], [@pone.0112731-Ruutu1], [@pone.0112731-Park1] ([Table 1](#pone-0112731-t001){ref-type="table"}), we determined that the combination of low-dose LMWH, PTX and UDCA appeared to be the most promising option for further evaluation with BT. We believe that our success in showing a benefit in ameliorating fRILI with this combination is based on the following factors: a highly homogeneous patient cohort; attention to patient compliance to the prophylactic regimen; and direct measurement of damage to the liver parenchyma rather than clinical endpoints.

The treatment course of 8 weeks for the medication was determined on the assumption that occurrence of RILD and fRILI peaks around 2 months after radiation-exposure [@pone.0112731-Lawrence1], [@pone.0112731-Ricke2], [@pone.0112731-Seidensticker2], [@pone.0112731-Wybranski1]. However, our findings suggest that the radiation-induced injury to the liver structures and cell endothelial continues beyond 8 weeks and that discontinuation of the medication at this time allows the development of a veno-occlusive state/liver cell dysfunction. Endothelial cell damage, which triggers local thrombotic mechanisms, leading to microvascular flow insufficiency, production of cytotoxic substances, and ultimately hepatocellular necrosis, has been thought to be an early event in the development of RILD/VOD [@pone.0112731-Lawrence1], [@pone.0112731-Farthing1], [@pone.0112731-Fajardo1], [@pone.0112731-Catani1], [@pone.0112731-Geraci1]. The current evidence indicates that PTX, low-dose LMWH and UDCA may act through a variety of mechanisms to alleviate these effects. PTX, for example, down regulates tumor-necrosis factor-α (TNF-α), a prime suspect in either the initiation or amplification of tissue injury following radiation. PTX also stimulates vascular endothelial production of non-inflammatory prostaglandins of the E- and I-series, enhancing loco-regional blood flow and promoting thrombolysis [@pone.0112731-Bianco1].

LMWHs are assumed to prevent subsequent thrombosis of hepatic venules after endothelial damage and therefore decrease the risk of VOD/RILD [@pone.0112731-Forrest1].

By oral administration of UDCA the concentration of potentially liver toxic hydrophobic bile acids can be reduced [@pone.0112731-Kowdley1]. Several *in vitro* studies suggest that potential attenuating effects of UDCA on the pathogenesis of VOD is achieved through the down-regulation of inflammatory cytokine such as TNF-α and interleukin-1 [@pone.0112731-Neuman1]. These cytokines not only induce and amplify liver damage but are also associated with apoptosis in endothelial cells [@pone.0112731-Lindner1] and the development of VOD. UDCA also appears to have a direct effect on programmed-cell death, inhibiting apoptosis and protecting against the membrane damaging effects associated with hydrophobic bile acids in both hepatocytes and non-liver cells [@pone.0112731-Rodrigues1].

The rationale for this combined treatment approach is based on the assumption that LMWH, PTX and UDCA, which act through a variety of different mechanisms, may act synergistically or in a complimentary fashion to protect the liver [@pone.0112731-Shulman2], [@pone.0112731-Lakshminarayanan1], [@pone.0112731-Park1]; although further study is needed to fully evaluate this hypothesis. However, based on the low toxicity profile of these medications, we believe that this initial approach can be justified. Although the patient numbers are small, the absence of severe toxicities acccords with experience of other published data [@pone.0112731-Attal2], [@pone.0112731-Bianco1], [@pone.0112731-Essell1], [@pone.0112731-Ohashi1], [@pone.0112731-Or1], [@pone.0112731-Ruutu1], [@pone.0112731-Park1].

Regarding changes of laboratory values, no clinically relevant (grade 3/4) toxicities were observed. The observed slight increases (varying over time and group) of fibrinogen, factor-VIII-activity, protein-S-activity and von-Willebrand-factor-activity correspond most likely to an unspecific increase in acute-phase proteins after radiotherapy or/and to a consequence of radiation-induced endothelial damage of the hepatic veins and sinuses with subsequent platelet aggregation. Regarding the course of liver specific laboratory paramters after BT, it might be argued that the induced fRILI was possibly too small to induce a significant overall increase of these parameters. However, the slight but significant increase of aspartate transaminase in the control group indicates a parenchymal damage. Interestingly, this increase was not seen in the treatment group, indicating a decreased parenchymal damage under preventive medication.

The primary endpoint in our analysis is based on a surrogate i.e. fRILI visualized and quantified using hepatobiliary contrast agent (Gd-EOB-DTPA)-enhanced MRI. Hepatobiliary contrast agents differ from other gadolinium chelates in that they are selectively taken up by functioning hepatocytes through an organic-anion-transporter-polypeptide (mainly OATP1B1 and 3) and excreted into the bile by the multidrug-resistance-protein-2. For Gd-EOB-DTPA, the biliary excretion rate is approximately 50% in humans [@pone.0112731-Pascolo1], [@pone.0112731-SchuhmannGiampieri1]. Regardless of the mechanism of damage to liver, the hepatobiliary contrast media in functionally altered liver parenchyma is significantly reduced [@pone.0112731-Watanabe1]. This is also true for fRILI since a loss of uptake of hepatobiliary contrast media is clearly evident in the liver parenchyma adjacent to the clinical target volume after local radiotherapy ([Figure 2](#pone-0112731-g002){ref-type="fig"}) [@pone.0112731-Ricke2], [@pone.0112731-Seidensticker2]. Importantly, an agreement has been found between the histopathological evidence of fRILI/VOD and loss of hepatocellular uptake of hepatobiliary contrast agent [@pone.0112731-Seidensticker3].

Unlike the reduced uptake of hepatobiliary contrast agents in sinusoidal-obstruction-syndrome observed after platinum-containing chemotherapy (which is reticular in geometry and generalized all over the liver) [@pone.0112731-Shin1], the reduced uptake of hepatobiliary contrast media after BT is focal, homogenous and circumferential around the clinical target volume ([Figure 1](#pone-0112731-g001){ref-type="fig"}) [@pone.0112731-Ricke2], [@pone.0112731-Seidensticker2]. Thus, we believe that we can exclude underlying sinusoidal-obstruction-syndrome as a confounder of our results. Additionally, the history of platinum-containing chemotherapy was equal between the groups and without influence on the endpoint.

We suggest that our study results can be transferred to other established radiation treatment methods of liver malignancies such as ^90^Y-radioembolization. According to conversion calculations, the dose ranges in the liver parenchyma associated with ^90^Y-radioembolization and BT are comparable, if re-calculated with respect to the standard fractionation. We therefore hypothesize that preventive treatment approaches against RILD/REILD should be equally effective for both ^90^Y-radioembolization and BT.

Conclusions {#s5}
===========

In summary, our results show a highly significant reduction in fRILI after BT of colorectal liver metastases in patients who received low-dose LMWH, PTX and UDCA. Further on, we believe that these findings can be adopted for the prevention of radiation-induced liver damage after other radiotherapeutic approaches as ^90^Y-radioembolization and that further clinical studies in this area are warranted.
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